In patients with nodular goiters that cause symptomatic or cosmetic problems, surgical or medical treatment is currently indicated \[[@b1-ceo-2020-00164]-[@b3-ceo-2020-00164]\]. However, complications such as incision scars or postoperative hypothyroidism can occur after thyroidectomy. Previous studies have shown that ultrasonography (USG)-guided radiofrequency ablation (RFA) under local anesthesia has a similar efficacy to that of surgery and can serve as an alternative treatment for benign nodular goiters \[[@b3-ceo-2020-00164]-[@b6-ceo-2020-00164]\]. However, few studies have investigated the usefulness of RFA in patients with nodular goiters who have previously undergone unilateral lobectomy. Therefore, the aim of this study was to evaluate the efficacy of USG-guided RFA in patients with benign thyroid goiters who had previously undergone unilateral lobectomy and to evaluate whether RFA affected thyroid function in these patients.

Patients presenting to the Department of Otorhinolaryngology-Head and Neck Surgery at Soonchunhyang University Bucheon Hospital between February 2013 and December 2018 were prospectively studied. In total, 160 consecutive RFA procedures were performed in patients with solid or predominantly solid benign thyroid nodules that were cosmetically problematic or symptomatic. Of these patients, 14 had a history of unilateral lobectomy. This study was approved by the Institutional Review Board of the Soonchunhyang University College of Medicine (IRB No. SCHBC_IRB_2011-21). All patients provided written informed consent.

The exclusion criteria were as follows: (1) patients with a nodule measuring \<10 mm, (2) follicular neoplasm or malignancy on fine-needle aspiration (FNA), (3) USG findings suspicious for malignancy, and (4) previous radiotherapy or sclerosing therapy. USG examinations, FNA findings, thyroid function, and clinical concerns were evaluated before RFA. All patients underwent two USG-guided FNA biopsies to confirm whether the nodule was malignant and whether occult metastasis was present prior to the procedure. USG and USG-guided FNA were performed using a 12L--RS linear probe fitted to an ultrasound scanner system (LOGIQ P9, GE Healthcare, Seoul, Korea). The nodule volume was calculated as length width×height×π/6 (or ×0.52).

To score the symptoms caused by the nodular goiters, patients were asked to rate their symptoms on a 10-cm visual analog scale, ranging from 1 (no symptoms) to 4 (most severe symptoms). Physicians recorded a cosmetic score (1, no palpable mass; 2, no cosmetic problem, but a palpable mass; 3, a cosmetic problem on swallowing only; and 4, a readily detected cosmetic problem) \[[@b7-ceo-2020-00164]\]. A single surgeon (SWL) performed RFA using an radiofrequency generator (VIVA RF generator; STARmed, Goyang, Korea) and an 18-gauge, 5-mm or 7-mm tip internally cooled electrode (Well-point RF Electrode, STARmed). The tip was inserted into the nodule under USG guidance. All nodules were treated using the transisthmic approach and the movingshot technique \[[@b3-ceo-2020-00164],[@b6-ceo-2020-00164]\]. After RFA, patients were admitted to check for postoperative complications; if they did not experience any complications, they were discharged the following day.

Statistical analyses were performed using SPSS ver. 18.0 (SPSS Inc., Chicago, IL, USA). Variables were compared using the Wilcoxon sign-rank test at the time of the first visit and at the follow-up visit. The significance level was defined as *P*\<0.05. Demographic data such as age, procedure time, and components of the nodule did not differ significantly according to whether patients had undergone unilateral lobectomy (*P*\>0.05). The mean cosmetic score decreased from 3.14±0.95 at the first visit to 1.14±0.36 at the 6-month follow-up and 1.14±0.36 at the 12-month follow-up (*P*\<0.001). However, the symptom score did not change significantly at the 6- and 12-month follow-ups (*P*\>0.05) ([Table 1](#t1-ceo-2020-00164){ref-type="table"}).

At the first visit, the mean nodule volume was 4.49±0.99 mL. After RFA, the mean nodule volume decreased significantly to 1.05±0.6 mL at the 6-month follow-up and 0.63±0.55 mL at the 12-month follow-up (*P*\<0.001) ([Table 1](#t1-ceo-2020-00164){ref-type="table"}). The mean percentage of volume reduction demonstrated a similar trend, increasing from 79.4%±17.6% at the 6-month follow-up to 81.2%±10.5% at the 12-month follow-up (*P*\<0.001). Thyroid function was assessed by measuring triiodothyronine (T~3~), free thyroxine (T~4~), and thyroid-stimulating hormone (TSH) levels, none of which significantly changed after RFA (*P*\>0.05) ([Table 2](#t2-ceo-2020-00164){ref-type="table"}). No major complications such as permanent vocal cord paralysis, dyspnea, major vessel injury, esophagus injury, or thyrotoxicosis were observed during the follow-up period. In accordance with other studies demonstrating that the rate of recurrence was low, no regrowth of treated nodules in this study was observed \[[@b2-ceo-2020-00164],[@b4-ceo-2020-00164],[@b8-ceo-2020-00164]\].

In the present study, RFA was found to be an effective and safe treatment, considering that the nodule volume was reduced by \>50% and cosmetic improvements were achieved without major complications. However, RFA did not lead to statistically significant improvements in symptoms. As there were some patients in our study with huge thyroid goiters that were large enough to compress surrounding structures, resulting in a variety of symptoms, the improvements in symptom scores in the patients in our study were not statistically significant. Unlike other studies, thyroid function tests including measurements of T~3~, free T~4~, and TSH levels were undertaken before and after RFA to determine whether RFA affected thyroid function in patients with nodular goiters who had previously undergone unilateral thyroidectomy. Seven patients in our study who did not receive T~4~ supplementation therapy before RFA maintained their thyroid function without the need for additional T~4~ supplementation after RFA. The other seven patients who took T~4~ supplements before RFA showed stable thyroid function, without an increase in the therapeutic dose after the procedure. These findings indicate that RFA did not cause thyroid function to deteriorate in patients who had undergone unilateral lobectomy.

Generally, open surgery for patients with only one functioning thyroid gland poses an elevated risk of recurrent laryngeal nerve injury and hypoparathyroidism, as well as inevitable permanent hypothyroidism resulting from the procedure \[[@b5-ceo-2020-00164],[@b6-ceo-2020-00164],[@b9-ceo-2020-00164]\]. Therefore, after the surgical procedure, patients must take medications for the rest of their life to control their thyroid function. According to the results of our study, for patients with nodular goiters who had previously undergone unilateral thyroidectomy, RFA---as opposed to open surgery---could lower the risk of these complications and the need for lifelong medications, without influencing thyroid function. In conclusion, RFA resulted in significant volume reduction without any serious complications or alteration of thyroid function, meaning that it can be used to treat benign solid nodular goiters that cause cosmetic or symptomatic problems in patients who have undergone unilateral lobectomy.
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###### 

Clinical data obtained at the first visit and at the 6- and 12-month follow-ups

  Characteristics                                                   First visit   6-Month follow-up   *P*-value   12-Month follow-up   *P*-value^[c)](#tfn3-ceo-2020-00164){ref-type="table-fn"}^
  ----------------------------------------------------------------- ------------- ------------------- ----------- -------------------- ------------------------------------------------------------
  Diameter (cm)                                                     3.07±0.86     1.31±0.49           \<0.001     0.96±0.58            \<0.001
  Volume (mL)                                                       4.49±0.99     1.05±0.60           \<0.001     0.63±0.55            \<0.001
  Symptom score^[a)](#tfn1-ceo-2020-00164){ref-type="table-fn"}^    1.29±0.61     1.14±0.36           0.157       1.07±0.26            0.180
  Cosmetic score^[b)](#tfn2-ceo-2020-00164){ref-type="table-fn"}^   3.14±0.95     1.14±0.36           \<0.001     1.14±0.36            \<0.001

Values are presented as mean±standard deviation.

Patients were asked to rate their symptoms on a 10-cm visual analog scale, ranging from 1 (no symptoms) to 4 (most severe symptoms).

Patients expressed their cosmetic problems on a 4-point scale (1, no palpable mass; 2, no cosmetic problem, but a palpable mass; 3, a cosmetic problem on swallowing only; and 4, a readily detected cosmetic problem).

First visit vs. 12-month follow-up.

###### 

Thyroid function tests performed at the first visit and at 6- and 12-month follow-ups for the seven patients who did not take Synthyroid before and after RFA

  Characteristics     First visit   6-Month follow-up   *P*-value   12-Month follow-up   *P*-value^[a)](#tfn4-ceo-2020-00164){ref-type="table-fn"}^
  ------------------- ------------- ------------------- ----------- -------------------- ------------------------------------------------------------
  T~3~ (ng/dL)        1.11±0.22     1.26±0.42           0.175       1.13±0.35            0.123
  Free T~4~ (ng/dL)   1.15±0.21     1.08±0.06           0.168       1.13±0.11            0.173
  TSH (μIU/mL)        2.91±0.21     3.15±0.61           0.265       3.13±0.41            0.285

Values are presented as mean±standard deviation.

RFA, radiofrequency ablation; T~3~, triiodothyronine; T~4~, thyroxine; TSH, thyroid-stimulating hormone.

First visit vs. 12-month follow-up.
